



Oregon Prescription Drug Affordability Board Regular Meeting

Wednesday, December 17, 2025

Minutes approved by the board on Jan. 21, 2026

Web link to the meeting video: <https://youtu.be/zTyUMuPgpOs>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20251217-PDAB-document-package.pdf>

Call to order: Chair Shelley Bailey called the meeting to order at 8:03 a.m.

Roll call:

Present: Chair Shelley Bailey, Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, and John Murray

Arrived late: Chris Laman (8:21 a.m.)

Absent: None

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: John Murray provided a statement. View at video minute [00:01:02](#).

Approval of board minutes: Chair Bailey approved by consensus the Nov. 19, 2025 minutes as shown on [Pages 3-4](#) of the agenda materials. View at video minute [00:02:08](#).

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View the video at minute [00:02:28](#).

General public comment: Public comment was received from the following individuals who signed up in advance: Dharia McGrew, PhRMA; Jessica McBride, Oregon Coalition for Affordable Prescriptions; Ranier Simons, Community Access National Network; and Lorren Sandt, Caring Ambassadors. The board received 7 written comments, which are posted on the [PDAB website](#). View at video minute [00:09:23](#).

Board discussion and vote on annual report: Board members discussed the 2025 annual report and proposed amendments. The board voted unanimously to approve the amended 2025 annual report and submit it to the Oregon Legislature. The approved [annual report](#) is posted on the PDAB website. View the discussion and vote at video minute [00:19:26](#).



MOTION to approve the 2025 annual report as amended by the board today and deliver to the Oregon Legislature by Dec. 31, 2025, as required by ORS 646A.696.

Board Vote:

Motion: Chris Laman

Second: John Murray

Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey

No: None

Absent: None

MOTION PASSED 7-0

2026 drug review – presentation of the prescription drugs and insulin products preliminary lists:

The board received the draft preliminary lists of prescription drugs and insulin products for the 2026 drug reviews, based on commercial insurer reporting from calendar year 2024. The board began reviewing the list at the Dec. 17 meeting and will continue reviewing and narrowing the lists for further evaluation in 2026. The [preliminary list](#) of drugs is posted on the PDAB website. View at video minute [00:44:57](#).

2025 drug review – continued review of the prescription drugs and insulin products: The board continued its review of the prescription drug and insulin products. The board reviewed 23 prescription drugs and insulin products during its meetings in July, August, September, and October, with additional discussions in November and December. The board will vote in January on a list of up to nine prescription drugs and at least one insulin product for inclusion in a report to the Oregon Legislature in March. Drug reviews are conducted according to ORS 646A.694 and OAR 925-200-0020. Read the detailed [reports for each drug](#) posted on the PDAB website. View at video minute [01:39:25](#).

Announcements: Chair Bailey announced the next board meeting will be Jan. 21, 2026 at 8 a.m. View at video minute [03:31:43](#).

Adjournment: Chair Bailey adjourned the meeting at 12 p.m. with all board members in agreement. View at video minute [03:31:57](#).